Skip to main content
SpringerLink
Log in

From the World Literature

  • News
  • Published:
Molecular Diagnosis & Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Hoskins JM, Marcuello E, Altes A, et al. Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res 2008 Mar 15; 14(6): 1788–96

    Article  PubMed  CAS  Google Scholar 

Reference

  • Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008 Oct 1; 112(7): 2687–93

    Article  PubMed  CAS  Google Scholar 

References

  1. Ahn M-J, Park B-B, Ahn JS, et al. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clin Cancer Res 2008 Jun 15; 14(12): 3860–6

    Article  PubMed  CAS  Google Scholar 

  2. Felip E, Rojo F, Reck M, et al. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 2008 Jun 15; 14(12): 3867–74

    Article  PubMed  CAS  Google Scholar 

References

  1. O’Shaughnessy J, Blackwell KL, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy [abstract no. 1015]. 44th Annual Meeting of the American Society of Clinical Oncology; 2008 May 30–Jun 3; Chicago (IL)

  2. Slamon D, Gomez HL, Kabbinavar FF, et al. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2—positive advanced or metastatic breast cancer [abstract no. 1016]. 44th Annual Meeting of the American Society of Clinical Oncology; 2008 May 30–Jun 3; Chicago (IL)

Reference

  • Ekwueme DU, Gardner JG, Subramanian S, et al. Cost analysis of the National Breast and Cervical Cancer Early Detection Program: selected states, 2003 to 2004. Cancer 2008 Feb 1; 112(3): 626–35

    Article  PubMed  Google Scholar 

Reference

  • Yu H, Lin S, Zhang Y, et al. Intron-2 conversion polymorphism of the aldosterone synthase gene and the antihypertensive response to angiotensin-converting enzyme inhibitors. J Hypertens 2008 Feb; 26(2): 251–6

    Article  PubMed  CAS  Google Scholar 

Reference

  • de Denus S, Zakrzewski-Jakubiak M, Dubé M-P, et al. Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan. Ann Pharmacother 2008 Jul; 42(7): 925–32

    Article  PubMed  Google Scholar 

References

  1. Iakoubova OA, Tong CH, Rowland CM, et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective studies: CARE and WOSCOPS. J Am Coll Cardiol 2008 Jan 29; 51(4): 435–43

    Article  PubMed  CAS  Google Scholar 

  2. Iakoubova OA, Sabatine MS, Rowland CM., et al. Polymorphism in K1F6 gene and benefit from statins after acute coronary syndromes. J Am Coll Cardiol 2008 Jan 29; 51(4): 449–55

    Article  PubMed  CAS  Google Scholar 

  3. Shiftman D, Chasman, DI, Zee RY, et al. A kinesin family member 6 (K1F6) variant is associated with coronary heart disease in the Women’s Health Study [erratum in: J Am Coll Cardiol 2008 Mar 4; 51 (9): 977]. J Am Coll Cardiol 2008 Jan 29; 51(4): 444–8

    Article  Google Scholar 

Reference

  • ARCA biopharma Inc. Bucindolol significantly reduces hospitalization and death in heart failure patients with very favorable genotypes. Media release: 2008 Sep 22 [online]. Available from URL: http://www.arcabiopharma.com [Accessed 2008 Nov 21]

References

  1. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med 2008 Aug 21; 359(8): 789–99

    Article  Google Scholar 

  2. Nakamura Y. Pharmacogenomics and drug toxicity. N Engl J Med 2008 Aug 21; 359(8): 856–8

    Article  PubMed  CAS  Google Scholar 

Reference

  • Kalliokoski A, Neuvonen M, Neuvonen PJ, et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol 2008 Mar; 48(3): 311–21

    Article  PubMed  CAS  Google Scholar 

References

  1. Yu X, Park BH, Wang MY, et al. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc Natl Acad Sci U S A 2008 Sep 16; 105(37): 14070–5

    Article  PubMed  CAS  Google Scholar 

  2. UT Southwestern Medical Center. Scientists discover leptin can also aid type 1 diabetics. Media release: 2008 Aug 25 [online]. Available from URL: http://www.newswise.com [Accessed 2008 Nov 21]

Reference

  • Globelmmune. Globelmmune hepatitis C therapeutic vaccine, GI-5005, doubles viral clearance and increases RVR rates in phase 2 clinical trial. Media release: 2008 Nov 1 [online]. Available from URL: http://www.globeimmune.com [Accessed 2008 Nov 21] University of Illinois at Chicago. Scientists discover how some bacteria survive antibiotics. Media release: 2008 Apr 30 [online]. Available from URL: http://www.newswise.com [Accessed 2008 Nov 21]

Reference

  • Schackman B, Scott C, Walensky R, et al. Genetic testing in HIV care: clinical effect and cost-effectiveness of HLA-B*5701 screening to guide first-line abacavir use [abstract no. 911]. 15th Conference on Retroviruses and Opportunistic Infections; 2008 Feb 3–6; Boston (MA)

Reference

  • Acuna-Villaorduna C, Vassall A, Henostroza G, et al. Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin Infect Dis 2008 Aug; 47(4): 487–95

    Article  PubMed  Google Scholar 

Reference

  • Abe T, Seo T, Ishitsu T, et al. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br J Clin Pharmacol 2008 Aug; 66 (2): 304-7 Neurologix Inc. Neurologix initiates recruitment for phase 2 Parkinson’s disease trial. Media release: 2008 Aug 20 [online]. Available from URL: http://www.neurologix.net [Accessed 2008 Nov 21]

References

  1. Bleecker ER, Postma DS, Lawrance RM, et al. Effect of ADRB2 polymorphisms on response to longacting beta-2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007 Dec 22; 370(9605): 2118–25

    Article  PubMed  CAS  Google Scholar 

  2. Taylor DR, Hall IP. ADRB2 polymorphisms and beta-2 agonists. Lancet 2007 Dec 22; 370(9605): 2075–6

    Article  PubMed  CAS  Google Scholar 

References

  1. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008 Aug 30; 372(9640): 719–27

    Article  PubMed  CAS  Google Scholar 

  2. Hyde SC, Gill DR. Ignoring the nonsense: a phase II trial in cystic fibrosis. Lancet 2008 Aug 30; 372(9640): 691–2

    Article  PubMed  Google Scholar 

Reference

  • Mersereau JE, Plunkett BA, Cedars MI. Preimplantation genetic screening in older women: a cost-effectiveness analysis. Fertil Steril 2008 Sep; 90(3): 592–8

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

From the World Literature. Mol Diag Ther 12, 405–412 (2008). https://doi.org/10.1007/BF03256307

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03256307

Search

Navigation